DTDEC-01 is under clinical development by Dystrogen Therapeutics and currently in Phase I for Duchenne Muscular Dystrophy. According to GlobalData, Phase I drugs for Duchenne Muscular Dystrophy have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DTDEC-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - DTDEC-01 in Duchenne Muscular Dystrophy

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DTDEC-01 overview

DTDEC-01 is under development for the treatment of Duchenne muscular dystrophy (DMD). The therapeutic candidate is a dystrophin expressing chimeric (DEC) cell therapy. It consists of ex-vivo fused autologous human bone marrow-derived mesenchymal stem cell with allogeneic human myoblast encoding dystrophin gene. The therapy enhances engraftment and eliminates the need for immunosuppression. It is administered through intraarticular (intra-bone) and Intraosseous route.

Dystrogen Therapeutics overview

Dystrogen Therapeutics is a clinical stage regenerative medicine company focused on the development of medicines for rare diseases. The company developed dystrophin expressing chimeric (DEC) therapy to treat patients with Duchenne muscular dystrophy. It combines duchenne cell with a cell of healthy donor that allows the patients’ body and immune system to accept the new dystrophin producing cells that can engraft inside the patient’s muscles and increase their dystrophin levels. The company is funded by StarFinder and other private investors for advancing chimeric cell therapy to clinical application in Duchenne patients. Dystrogen Therapeutics is headquartered in Poznan, Poland.

For a complete picture of DTDEC-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 4 December 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.